Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04895579
Title Lung Cancer With Copanlisib and Durvalumab (LCD)
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Zhonglin Hao
Indications

lung non-small cell carcinoma

Therapies

Copanlisib + Durvalumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST